Cancer Drug Kadcyla Must Be Called By Full Name, FDA Says
The U.S. Food and Drug Administration on Monday urged health care professionals and publications to use the full generic name of Genentech Inc.'s breast cancer treatment Kadcyla when referring to the...To view the full article, register now.
Already a subscriber? Click here to view full article